Newsweed Report: German Medical THC Prices Vary 12-Fold

What the Newsweed report shows, and what it doesn't

Newsweed reported on Oct. 17 that THC prices in Germany's medical cannabis market vary by a factor of 12. The signal available for this story carries the headline only.

That means the price range, the unit of measure, the sample size and the collection date are all unconfirmed here. We don't know whether Newsweed compared price per gram, price per milligram of THC, or list prices against dispensed prices. Each choice produces a different spread.

So treat the 12x figure as Newsweed's finding, not as a verified market constant. CannIntel hasn't independently reviewed the underlying dataset.

Still, the headline number is a useful stress test. Mature commodity markets don't usually tolerate a 12x spread for long.

Why a 12x gap can't come from potency alone

A twelvefold difference in THC price is too large to be explained by potency differences within a single product category. Dried flower is measured in percent THC, and the top and bottom of that scale sit far closer together than 12 to 1.

Something else is driving the gap. The candidates below are hypotheses based on how the market is structured, not findings from the Newsweed report:

• Product format. Flower, extracts and other formats carry different cost structures, and a blended comparison can inflate any spread.
• Supply chain layers. Importer, wholesaler, pharmacy and, increasingly, telemedicine platform each take a cut before the patient pays.
• Branding and genetics. Premium cultivars such as Wedding Cake or Northern Lights-lineage flower can command a price well above commodity-grade material.
• Denominator choice. Pricing per mg of THC rewards high-potency products and penalizes low-potency ones, which widens the measured gap.

Not every one of these drivers is equally durable. Branding premiums can last. Opaque intermediary markups tend not to.

Patients feel this first. Statutory insurers and self-pay patients can face very different bills for what is clinically a similar dose. That isn't a market working cleanly.

What operators and investors should check next

The spread matters most as a diagnostic for average selling price and gross margin in German sales, not as a headline number. Germany became a focal market after the Cannabis Act took effect on April 1, 2024, and medical cannabis was moved out of the Narcotics Act. Import-dependent suppliers have competed for that volume since.

For a company with German exposure, a wide price dispersion cuts two ways. High-priced sellers may be exposed to price compression if buyers become more price-aware. Low-priced sellers may be running thin margins that don't survive a cost shock.

The questions below belong on any earnings-call list for operators with German sales:

1. Average selling price per gram in the German segment, quarter over quarter.
2. Gross margin movement in basis points and how much of it traces to German mix.
3. Channel split between pharmacy wholesale, direct-to-pharmacy and platform partners.
4. Price concessions or rebates disclosed in segment notes, and whether management calls them temporary.
5. Inventory write-downs tied to German product that sat unsold.

None of these is answered by Newsweed's headline, but all of them can be answered from filings and call transcripts. A 12x spread is a prompt to read the segment disclosures closely, not a reason to reprice a stock.

The opinion read: a spread this wide usually means the market is still discovering its price, and that tends to favor operators with low-cost supply and transparent channels. Operators leaning on opaque markups should worry.

For full background on this story, see the CannIntel topic hub on the Germany medical cannabis market.

The next signal: third-quarter filings from operators with German sales, where per-gram pricing and German gross margin will show whether the Newsweed spread is showing up in reported numbers.